Relation Between Cost Driven Green Kaizen and Pharmaceutical Production
DOI:
https://doi.org/10.61841/tjv3kj91Keywords:
Cost Driven, Change Management, Environmental Improvement, Kaizen, Green Kaizen, Opex, Lean SustainabilityAbstract
A case study of green kaizen shows how operators and managers can use the Green Performance Map method in a drug manufacturer to engage in environmental improvements on a shopping floor. The method involves defining possibilities for development, an input-output visualizing model (to achieve a common understanding) and a cost saving strategy for intervention prioritizing (to reach strength). This paper would illustrate how operationalization is necessary to change behavior, and illustrates how cost is used to achieve environmental change. The necessary changes are enormous and have begun. In conjunction with new technology exponential development and the overall digitalization, this research find a mode of processing for the producing sector. There are people who say that they are aware of the industrial revolution for the first time in history. There are however significant differences of future manufacturing transition vs. current factories, i.e. brownfield, based upon the preconditions of each company to operate with new Greenfield factories.
Downloads
References
[1] M. Bellgran, M. Kurdve, and R. Hanna, “Cost driven green kaizen in pharmaceutical production – Creating positive engagement for environmental improvements,” in Procedia CIRP, 2019.
[2] A. B. Pampanelli, P. Found, and A. M. Bernardes, “A Lean & Green Model for a production cell,” J. Clean. Prod., 2014.
[3] C. Wiles and P. Watts, “Continuous flow reactors: A perspective,” Green Chemistry. 2012.
[4] K. Kümmerer and M. Hempel, Green and sustainable pharmacy. 2010.
[5] S. A. Kelly et al., “Application of ω-Transaminases in the Pharmaceutical Industry,” Chemical Reviews. 2018.
[6] A. Cherrafi et al., “Green and lean: a Gemba–Kaizen model for sustainability enhancement,” Prod. Plan. Control, 2019.
[7] R. Wohlgemuth, I. Plazl, P. Žnidaršič-Plazl, K. V. Gernaey, and J. M. Woodley, “Microscale technology and biocatalytic processes: Opportunities and challenges for synthesis,” Trends in Biotechnology. 2015.
[8] A. Brasco, P. Found, and A. Moura, “A Lean and Green Kaizen Model,” 2011 POMS Annu. Conf., 2011.
[9] S. J. Burgess, B. Tamburic, F. Zemichael, K. Hellgardt, and P. J. Nixon, “Solar-driven hydrogen production in green algae,” in Advances in Applied Microbiology, 2011.
[10] A. Isidro-Llobet et al., “Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production,” J. Org. Chem., 2019.
[11] M. J. Raymond, C. S. Slater, and M. J. Savelski, “LCA approach to the analysis of solvent waste issues in the pharmaceutical industry,” Green Chem., 2010.
[12] S. Aflaki, P. R. Kleindorfer, and V. S. De Miera Polvorinos, “Finding and implementing energy efficiency projects in industrial facilities,” Prod. Oper. Manag., 2013.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
